Eudaimonia Partners’s Teladoc Health TDOC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$223K Hold
14,763
0.05% 236
2023
Q4
$318K Buy
14,763
+2,247
+18% +$41.5K 0.08% 181
2023
Q3
$233K Buy
12,516
+510
+4% +$11.9K 0.06% 278
2023
Q2
$304K Sell
12,006
-240
-2% -$6.04K 0.07% 249
2023
Q1
$317K Sell
12,246
-1,032
-8% -$27.6K 0.08% 250
2022
Q4
$314K Sell
13,278
-3,193
-19% -$86.1K 0.08% 248
2022
Q3
$418K Buy
16,471
+404
+3% +$14.2K 0.11% 183
2022
Q2
$534K Buy
16,067
+4,087
+34% +$174K 0.1% 209
2022
Q1
$864K Buy
+11,980
New +$863K 0.15% 170
2021
Q3
$786K Buy
6,195
+1,365
+28% +$199K 0.14% 175
2021
Q2
$803K Buy
4,830
+639
+15% +$104K 0.15% 167
2021
Q1
$762K Buy
4,191
+77
+2% +$17.9K 0.16% 149
2020
Q4
$823K Buy
4,114
+185
+5% +$37.6K 0.18% 129
2020
Q3
$861K Buy
3,929
+2,785
+243% +$590K 0.22% 111
2020
Q2
$218K Buy
1,144
+389
+52% +$68.2K 0.08% 224
2020
Q1
$117K Buy
755
+255
+51% +$29.7K 0.05% 303
2019
Q4
$42K Buy
+500
New +$38K 0.02% 529

Other funds holding TDOC

Eudaimonia Partners's TDOC Position: Q1 2024 in Review

Eudaimonia Partners held its Teladoc Health (TDOC) position steady in Q1 2024 at 14,763 shares worth $223K. The position accounts for 0.05% of the portfolio, ranked #236.

Eudaimonia Partners first reported a position in TDOC in Q4 2019 and has held it in 17 quarters since. The position peaked at $864K in Q1 2022. 426 funds tracked by Wall St. Rank hold TDOC as of Q1 2024.

  • Eudaimonia Partners held 14,763 shares of Teladoc Health worth $223K as of Q1 2024.
  • Eudaimonia Partners left its Teladoc Health share count unchanged in Q1 2024.
  • Teladoc Health made up 0.05% of Eudaimonia Partners's portfolio in Q1 2024, its #236 holding.
  • Eudaimonia Partners first reported a position in Teladoc Health in Q4 2019 and has held it in 17 quarters since.
  • Eudaimonia Partners's Teladoc Health position peaked at $864K in Q1 2022.
  • 426 funds tracked by Wall St. Rank held Teladoc Health as of Q1 2024.

Based on Eudaimonia Partners's 13F filing for Q1 2024, filed 25 Apr 2024.